Singular Genomics Systems (OMIC)
(Delayed Data from NSDQ)
$14.76 USD
+0.49 (3.44%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $14.43 -0.33 (-2.24%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$14.76 USD
+0.49 (3.44%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $14.43 -0.33 (-2.24%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
Similar Genomics Systems (OMIC) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Similar Genomics Systems (OMIC) delivered earnings and revenue surprises of 2.94% and 39.65%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Similar Genomics Systems (OMIC) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Similar Genomics Systems (OMIC) delivered earnings and revenue surprises of 21.62% and 27.50%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's Why Similar Genomics Systems (OMIC) Could be Great Choice for a Bottom Fisher
by Zacks Equity Research
Similar Genomics Systems (OMIC) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Similar Genomics Systems (OMIC) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Similar Genomics Systems (OMIC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
3 Healthcare Stocks Poised to Surpass Earnings Estimates in Q1
by Debasmita Chatterjee
Improved patient volumes, a diversified healthcare portfolio and various technological advancements are likely to favor first-quarter results of ELAN, DCGO and OMIC.